These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37966367)

  • 1. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Lerner SP; McConkey DJ; Tangen CM; Meeks JJ; Flaig TW; Hua X; Daneshmand S; Alva AS; Lucia MS; Theodorescu D; Goldkorn A; Milowsky MI; Choi W; Bangs R; Gustafson DL; Plets M; Thompson IM
    Clin Cancer Res; 2024 Jan; 30(2):444-449. PubMed ID: 37966367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Flaig TW; Tangen CM; Daneshmand S; Alva AS; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Sep; 84(3):341-347. PubMed ID: 37414705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
    Flaig TW; Tangen CM; Daneshmand S; Alva A; Lerner SP; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM
    Clin Cancer Res; 2021 May; 27(9):2435-2441. PubMed ID: 33568346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
    Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW
    Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
    JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
    Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
    Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
    Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
    Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
    Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
    Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
    Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
    Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
    Reike MJ; de Jong JJ; Bismar TA; Boorjian SA; Mian OY; Wright JL; Dall'Era MA; Kaimakliotis HZ; Lotan Y; Boormans JL; Black PC; Gibb EA
    Urol Oncol; 2024 Jun; 42(6):177.e5-177.e14. PubMed ID: 38480079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.